AUA 2023 - American Urological Association Annual Meeting
Apr 28 - May 01, 2023 | ChicagoILUS
LARVOL is not affiliated with American Urological Association Annual Meeting and all trademarks, logos, and brand names are property of their respective owners
Showing 105 abstracts linked to Trials
EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-Risk Biochemically Recurrent Prostate Cancer
First Results From SunRISe-1 in Patients With BCG Unresponsive High-Risk Non–muscle-Invasive Bladder Cancer Receiving TAR-200 in Combination With Cetrelimab, TAR-200, or Cetrelimab Alone
Neoadjuvant Pembrolizumab Shows Promise as Effective Systemic Therapy Prior to Radical Cystectomy for Cisplatin-Ineligible Muscle Invasive Bladder Cancer
Clinical fracture incidence in metastatic hormone-sensitive prostate cancer (mHSPC) and risk-reduction following addition of zoledronic acid to androgen deprivation therapy (ADT) with or without docetaxel (Doc): long-term results from 2 phase 3 trials from the STAMPEDE platform protocol
The Use of 68Ga-FAP-2286 PET Imaging in Patients with Localized Bladder Cancer
Prophylactic Use of Biologic Mesh in Ileal Conduit (PUBMIC): Initial Report of a Randomized Controlled Trial
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy
The Hematuria Cancer Risk Score: A validation study demonstrating reduction in the number needed to investigate while preserving fidelity of cancer detection
Real-world Study on Darolutamide, Enzalutamide, and Apalutamide for Nonmetastatic Castration-Resistant Prostate Cancer Patients Using a Urology Network in the United States (DEAR Study)
Infectious and Non-infectious Complications Following Prostate Biopsy: A Randomized Clinical Trial
Results from the extended follow-up in patients with muscle-invasive bladder cancer in the CheckMate 274 trial
CORE1: Phase 2 Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin (BCG)
Biology and performance of pre- and post-pembrolizumab (Pembro) Vesical Imaging-Reporting and Data System (VI-RADS) to predict the pathological response in muscle-invasive urothelial bladder cancer (MIBC): Full data analysis from a clinical trials pipeline
Treatment duration and long-term safety and tolerability with darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): ARAMIS Rollover Study
18F-rhPSMA-7.3 Detection Rates in Patients with Recurrence of Prostate Cancer Following Primary Treatment with Radiation Therapy: Results from the SPOTLIGHT Study